Heidi M.
- Country
- Czechia
- Department
- Hematologická klinika
Research Overview
- Phase 1b Study of Loncastuximab Tesirine with Anti-cancer Agents in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- INCB 50465-801: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsaclisib (INCB050465)
- Phase 3 Randomized Study of Tirabrutinib Versus Rituximab-Temozolomide in Relapsed/Refractory Primary Central Nervous System Lymphoma
Data & Insights
Has run more than one trial at 275 of 477 partner sites.
Specializations
Lymphoma Research
Specializes in the treatment of various forms of lymphoma, with particular emphasis on diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma. Investigates novel therapeutic approaches including antibody-drug conjugates and targeted therapies.
- Advanced B-cell lymphomas
- Follicular lymphoma
- Marginal zone lymphoma
- Primary mediastinal B-cell lymphoma
Leukemia Studies
Focuses on innovative treatments for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Explores combination therapies involving novel agents and established treatments.
- Treatment-naïve CLL
- Relapsed/refractory disease
- Cardiac-compromised patients
Treatment Approaches
Evaluates cutting-edge therapeutic strategies incorporating monoclonal antibodies, targeted therapies, and immunotherapy combinations. Investigates fixed-duration and MRD-guided treatment protocols.
- Novel drug combinations
- Immunotherapy regimens
- Chemotherapy optimization
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.